{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:15:19Z","timestamp":1780510519970,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011057","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T00:00:00Z","timestamp":1516579200000}}],"reference-count":185,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011057.pub2","type":"journal-article","created":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T17:18:16Z","timestamp":1516641496000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse"],"prefix":"10.1002","volume":"2018","author":[{"given":"Henk S","family":"Temmingh","sequence":"first","affiliation":[{"name":"University of Cape Town; Department of Psychiatry and Mental Health; Valkenberg Hospital Private Bage X1 Cape Town Western Cape South Africa 7935"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn","family":"Williams","sequence":"additional","affiliation":[{"name":"University of Cape Town; Department of Psychiatry and Mental Health; Valkenberg Hospital Private Bage X1 Cape Town Western Cape South Africa 7935"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandi","family":"Siegfried","sequence":"additional","affiliation":[{"name":"University of Cape Town; Department of Psychiatry and Mental Health; Valkenberg Hospital Private Bage X1 Cape Town Western Cape South Africa 7935"},{"name":"South African Medical Research Council; Alcohol, Tobacco and Other Drug Research Unit; Tygerberg South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan J","family":"Stein","sequence":"additional","affiliation":[{"name":"University of Cape Town; Department of Psychiatry and Mental Health; Valkenberg Hospital Private Bage X1 Cape Town Western Cape South Africa 7935"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,22]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD011057.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/10550490701389658","article-title":"Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia","volume":"16","author":"Akerele","year":"2007","journal-title":"American Journal on Addictions"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0002|cit2","unstructured":"Akerele EO Biderman L Levin FR A pilot study of olanzapine\/risperidone for the treatment of cocaine\/marijuana use disorder in individuals with schizophrenia 64th Annual Scientific Meeting of the College on Problems of Drug Dependence;2002 Jun 8-13, Quebec, Canada 2002"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011057.pub2-BIB0003|cit3","first-page":"S4","article-title":"Efficacy of atypical neuroleptics in treatment of substance use among schizophrenic individuals","volume":"66","author":"Akerele","year":"2002","journal-title":"Drug and Alcohol Dependence"},{"issue":"suppl_1","key":"10.1002\/14651858.CD011057.pub2-BIB0004|cit4","first-page":"297","article-title":"Clozapine versus other antipsychotics for schizophrenia and co-occurring cannabis use disorder","volume":"37","author":"Brunette","year":"2011","journal-title":"Schizophrenia Bulletin"},{"issue":"1-2","key":"10.1002\/14651858.CD011057.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/15504263.2011.570118","article-title":"A randomized trial of clozapine versus other antipsychotics for cannabis use disorder in patients with schizophrenia","volume":"7","author":"Brunette","year":"2011","journal-title":"Journal of Dual Diagnosis"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0006|cit6","unstructured":"NCT00149955 Cannabis and schizophrenia: effects of clozapine www.ClinicalTrials.gov\/ct\/show\/"},{"issue":"suppl_1","key":"10.1002\/14651858.CD011057.pub2-BIB0007|cit7","first-page":"145","article-title":"Differential effect of clozapine and risperidone on craving related brain activity in patients with schizophrenia and cannabis use disorder","volume":"37","author":"Machielsen","year":"2011","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0008|cit8","unstructured":"Machielsen MW Veltman DJ van den Brink W de Haan L Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study www.sciencedirect.com\/science\/article\/pii\/S0920996417301688"},{"issue":"7","key":"10.1002\/14651858.CD011057.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/0269881114527357","article-title":"The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: an fMRI study","volume":"28","author":"Machielsen","year":"2014","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0010|cit10","unstructured":"de Haan L Machielsen MWJ Effect of different antipsychotic medications on craving and craving related brain activity in patients with schizophrenia and cannabis abuse or dependence: a randomized controlled study comparing clozapine and risperidone www.trialregister.nl\/trialreg\/index.asp"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0011|cit11","unstructured":"NCT00573287 First episode schizophrenia and cannabis-related disorder study clinicaltrials.gov\/ct2\/show\/NCT00573287"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0013|cit12","unstructured":"Noordsy D First episode schizophrenia and cannabis abuse: is there a role for clozapine? Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15-18; Barcelona, Spain 2009"},{"issue":"2-3","key":"10.1002\/14651858.CD011057.pub2-BIB0012|cit13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.schres.2010.02.184","article-title":"Clozapine versus risperidone for people with first episode schizophrenia and co-occurring cannabis use disorder","volume":"117","author":"Noordsy","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0014|cit14","unstructured":"Noordsy DL Personal Communication Personal Communication 2012"},{"issue":"suppl_1","key":"10.1002\/14651858.CD011057.pub2-BIB0015|cit15","first-page":"355","article-title":"Clinical and substance use outcomes of first-episode schizophrenia patients with a lifetime diagnosis of cannabis use disorders randomly assigned to risperidone or olanzapine for 16 weeks","volume":"35","author":"Sevy","year":"2009","journal-title":"Schizophrenia bulletin"},{"issue":"3","key":"10.1002\/14651858.CD011057.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.psychres.2011.05.001","article-title":"Olanzapine versus risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes","volume":"188","author":"Sevy","year":"2011","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0018|cit17","unstructured":"Smelson D Nyhuis AW Faries DE Tunis SL Impact of substance use on attrition and medication switching in an effectiveness trial for individuals with schizophrenia: implications for relapse prevention. The American Psychiatric Association, 158th Annual meeting, Psychosomatic medicine: Integrating psychiatry and medicine; 2005 May 21-26; Atlanta, Georgia Arlington, VA American Psychiatric Association 2005"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011057.pub2-BIB0017|cit18","first-page":"A60","article-title":"Impact of substance use on attrition and medication switching in an effectiveness trial for individuals with schizophrenia","volume":"39","author":"Smelson","year":"2005","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011057.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/01.jcp.0000245562.99036.92","article-title":"Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use","volume":"26","author":"Smelson","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1-3","key":"10.1002\/14651858.CD011057.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.schres.2007.11.034","article-title":"The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study","volume":"100","author":"Swartz","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"supplement","key":"10.1002\/14651858.CD011057.pub2-BIB0021|cit21","first-page":"141","article-title":"Subjective well-being and craving for cannabis in first psychosis, a randomized double blind comparison of olanzapine versus risperidone","volume":"81","author":"Nimwegen","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD011057.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/070674370805300610","article-title":"Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial","volume":"53","author":"Nimwegen","year":"2008","journal-title":"Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie"},{"issue":"1","key":"10.1002\/14651858.CD011057.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00004714-199602000-00007","article-title":"Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients","volume":"16","author":"Blin","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD011057.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/npp.2010.111","article-title":"Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial [NCT00216476]","volume":"35","author":"Gaebel","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0025|cit25","unstructured":"Green A Cannabis and schizophrenia-clozapine vs risperidone www-commons.cit.nih.gov\/crisp\/index.html"},{"issue":"8","key":"10.1002\/14651858.CD011057.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.4088\/JCP.v68n0804","article-title":"Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study","volume":"68","author":"Harvey","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0027|cit27","unstructured":"Hassman H Glass S Krefetz D Pinho M Ridolfi E Engelhardt L Cognitive function and acute sedative effects of risperidone and quetiapine in patients with stable Bipolar I Disorder: a randomized, double-blind, crossover study 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15 Boca Raton, FL. 2006"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011057.pub2-BIB0028|cit28","first-page":"S133","article-title":"Differences in cognitive function and acute sedative effects of risperidone and quetiapine among individuals with stable Bipolar I Disorder","volume":"30","author":"Hassman","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011057.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pscychresns.2013.09.010","article-title":"Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis","volume":"221","author":"Ikuta","year":"2014","journal-title":"Psychiatry Research"},{"issue":"2-3","key":"10.1002\/14651858.CD011057.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.schres.2011.07.032","article-title":"Substance use and schizophrenia: adverse correlates in the CATIE study sample","volume":"132","author":"Kerfoot","year":"2011","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD011057.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-0031-1271688","article-title":"An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being","volume":"44","author":"Liemburg","year":"2011","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011057.pub2-BIB0032|cit32","first-page":"138","article-title":"A comparative study of risperidone and olanzapine in the treatment of mental disorders due to use of alcohol","volume":"14","author":"Liu","year":"2008","journal-title":"Chinese Magazine of Drug Abuse Prevention and Treatment"},{"issue":"1","key":"10.1002\/14651858.CD011057.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0920-9964(02)00231-1","article-title":"Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone","volume":"60","author":"Green","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0034|cit34","unstructured":"NCT00063349 Clozapine, cannabis and first episode schizophrenia www.ClinicalTrials.gov\/ct\/show\/"},{"issue":"10","key":"10.1002\/14651858.CD011057.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.4088\/JCP.13m08838","article-title":"Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial","volume":"76","author":"Green","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0036|cit36","unstructured":"NCT00130923 Risperidone long-acting for alcohol and schizophrenia treatment (R-LAST) www.ClinicalTrials.gov\/ct\/show\/"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0037|cit37","unstructured":"NCT00169026 Alcoholism and schizophrenia: effects of clozapine www.ClinicalTrials.gov\/ct\/show\/"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0038|cit38","unstructured":"NCT00498550 Cannabis and schizophrenia: effects of clozapine www.ClinicalTrials.gov\/ct\/show\/"},{"issue":"8","key":"10.1002\/14651858.CD011057.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4088\/JCP.v69n0808","article-title":"Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial","volume":"69","author":"Nejtek","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD011057.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.4088\/JCP.v67n1112","article-title":"Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial","volume":"67","author":"Perlis","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD011057.pub2-BIB0041|cit41","first-page":"733","article-title":"Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania","volume":"19","author":"Rezayat","year":"2014","journal-title":"Journal of Research in Medical Sciences"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011057.pub2-BIB0042|cit42","first-page":"S476","article-title":"Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: a long-term controlled study","volume":"15","author":"Rubio","year":"2005","journal-title":"European Neuropsychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD011057.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/070674370605100808","article-title":"Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity","volume":"51","author":"Rubio","year":"2006","journal-title":"Canadian Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011057.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4321\/S0213-61632006000300001","article-title":"Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: a long-term randomized, controlled, crossover study","volume":"20","author":"Rubio","year":"2006","journal-title":"European Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0045|cit45","unstructured":"Rubio G Martinez-Gras I Ponce G Jimenez-Arriero MA Lopez-Munoz F Alamo C Long-acting injectable risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity 159th Annual Meeting of the American Psychiatric Association; 2006, May 20-25 Toronto, Canada 2006"},{"issue":"7","key":"10.1002\/14651858.CD011057.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1176\/appi.ajp.159.7.1146","article-title":"Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety","volume":"159","author":"Sachs","year":"2002","journal-title":"American Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD011057.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4088\/JCP.v63n1211","article-title":"Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis","volume":"63","author":"Sajatovic","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011057.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.euroneuro.2004.06.003","article-title":"Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol [NCT00253162]","volume":"15","author":"Smulevich","year":"2005","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011057.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/JCP.0b013e318166f520","article-title":"Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis","volume":"28","author":"Nimwegen","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1600-0447.2007.01059.x","article-title":"A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder","volume":"434","author":"Yatham","year":"2007","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"10","key":"10.1002\/14651858.CD011057.pub2-BIB0051|cit51","first-page":"923","article-title":"Aripiprazole and risperidone in the treatment of schizophrenia","volume":"14","author":"Zhangyue","year":"2005","journal-title":"Chinese Journal of Behavioral Medical Science"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0052|cit52","unstructured":"Greenspan A Kosik-Gonzalez C Bossie C Zhu Y McLemore J Gharabawi G Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, Georgia, USA 2005 Nr279"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-10-26","article-title":"Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone [NCT00932529]","volume":"10","author":"Johnsen","year":"2010","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-244X-11-145","article-title":"Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial","volume":"11","author":"Kjelby","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0055|cit55","unstructured":"NCT00208143 Seroquel (quetiapine) therapy for schizophrenia and schizoaffective disorders and comorbid cocaine and\/or amphetamine abuse\/dependence: a comparative study with risperidone clinicaltrials.gov\/show\/NCT00208143"},{"issue":"2-3","key":"10.1002\/14651858.CD011057.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.psychres.2012.07.005","article-title":"One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis","volume":"200","author":"San","year":"2012","journal-title":"Psychiatry Research"},{"issue":"8","key":"10.1002\/14651858.CD011057.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/mp.2015.158","article-title":"Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial","volume":"21","author":"Yatham","year":"2016","journal-title":"Mol Psychiatry"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0058|cit58","unstructured":"Yatham L Atypical antipsychotics for continuation and maintenance treatment after an acute manic episode clinicaltrials.gov\/show\/NCT01977300 2003"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0059|cit59","unstructured":"NCT01639872 Clozapine for cannabis use in schizophrenia (CLOCS) clinicaltrials.gov\/ct2\/show\/NCT01639872"},{"issue":"7066","key":"10.1002\/14651858.CD011057.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD011057.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archpsyc.1982.04290070020005","article-title":"Negative symptoms in schizophrenia. Definition and reliability","volume":"39","author":"Andreasen","year":"1982","journal-title":"Archive of General Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011057.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.4088\/JCP.v67n0715","article-title":"A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia","volume":"67","author":"Ascher-Svanum","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011057.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4088\/JCP.09r05119gry","article-title":"Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review","volume":"71","author":"Baker","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"issue":"32","key":"10.1002\/14651858.CD011057.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.2174\/138161212802884834","article-title":"Treatment of cannabis use among people with psychotic disorders: a critical review of randomised controlled trials","volume":"18","author":"Baker","year":"2012","journal-title":"Current Pharmaceutical Design"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1192\/bjp.bp.106.024448","article-title":"Substance use in a population-based clinic sample of people with first-episode psychosis","volume":"190","author":"Barnett","year":"2007","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011057.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.puhe.2010.01.002","article-title":"Synthesizing diverse evidence: the use of primary qualitative data analysis methods and logic models in public health reviews","volume":"124","author":"Baxter","year":"2010","journal-title":"Public Health"},{"issue":"7108","key":"10.1002\/14651858.CD011057.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011057.pub2-BIB0069|cit69","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"6","key":"10.1002\/14651858.CD011057.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0278-5846(03)00176-3","article-title":"Acute and subacute effects of risperidone and cocaine on accumbens dopamine and serotonin release using in vivo microvoltammetry on line with open-field behavior","volume":"27","author":"Broderick","year":"2003","journal-title":"Progress in Neuro-psychopharmacology & Biological Psychiatry"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD011057.pub2-BIB0071|cit71","first-page":"5","article-title":"Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness","volume":"67","author":"Buckley","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011057.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1176\/appi.ajp.157.6.1019","article-title":"Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone","volume":"157","author":"Haan","year":"2000","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011057.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00213-002-1054-x","article-title":"Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale","volume":"162","author":"Haan","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0074|cit74","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28 Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0075|cit75","unstructured":"Deeks JJ Higgins JPT Altman DG editor(s) Chapter 9: Analysing data and undertaking meta-analyses Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011"},{"issue":"4","key":"10.1002\/14651858.CD011057.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/mpr.1362","article-title":"Craving for cannabis in patients with psychotic disorder, their non-affected siblings and healthy controls: psychometric analysis of the obsessive compulsive drug use scale","volume":"21","author":"Dekker","year":"2012","journal-title":"International Journal of Methods in Psychiatriatric Research"},{"issue":"21","key":"10.1002\/14651858.CD011057.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.291.21.2581","article-title":"Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys","volume":"291","author":"Demyttenaere","year":"2004","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD011057.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011057.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0006-3223(00)01038-6","article-title":"Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria","volume":"49","author":"Drevets","year":"2001","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD011057.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD011057.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/archpsyc.1978.01770310043002","article-title":"A diagnostic interview: the schedule for affective disorders and schizophrenia","volume":"35","author":"Endicott","year":"1978","journal-title":"Archive of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011057.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1023\/A:1025026619900","article-title":"Substance use among the mentally ill: a comparison of Italian and American samples","volume":"33","author":"Fioritti","year":"1997","journal-title":"Community Mental Health Journal"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0085|cit85","volume-title":"Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I-P, version 2)","author":"First","year":"1994"},{"issue":"10","key":"10.1002\/14651858.CD011057.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4088\/JCP.v64n1017","article-title":"Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic","volume":"64","author":"Fleischhacker","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011057.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/oxfordjournals.schbul.a033339","article-title":"Patterns of current and lifetime substance use in schizophrenia","volume":"24","author":"Fowler","year":"1998","journal-title":"Schizophrenia Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD011057.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0306-4603(01)00201-5","article-title":"Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire","volume":"27","author":"Franken","year":"2002","journal-title":"Addictive Behaviors"},{"issue":"4","key":"10.1002\/14651858.CD011057.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.pnpbp.2007.01.025","article-title":"Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice","volume":"31","author":"Fukushiro","year":"2007","journal-title":"Progress in Neuro-psychopharmacology & Biological Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD011057.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.brainresbull.2008.05.004","article-title":"Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice","volume":"77","author":"Fukushiro","year":"2008","journal-title":"Brain Research Bulletin"},{"issue":"7","key":"10.1002\/14651858.CD011057.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0093|cit93","first-page":"534","volume-title":"ECDEU Assessment Manual for Psychopharmacology-Revised","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011057.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World Journal of Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011057.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects","volume":"14","author":"Hasan","year":"2013","journal-title":"World Journal of Biological Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011057.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1080\/08897077.2011.599253","article-title":"The prevalence of substance use among psychiatric patients: the case study of Bugando Medical centre, Mwanza (northern Tanzania)","volume":"32","author":"Hauli","year":"2011","journal-title":"Substance Abuse"},{"issue":"1-3","key":"10.1002\/14651858.CD011057.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.drugalcdep.2008.12.010","article-title":"Reliability and validity of a short form of the Marijuana Craving Questionnaire","volume":"102","author":"Heishman","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0101|cit101","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD011057.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1002\/14651858.CD011057.pub2-BIB0103|cit103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000440","article-title":"Risperidone versus typical antipsychotic medication for schizophrenia","author":"Hunter","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011057.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/j.1440-1614.2000.00728.x","article-title":"Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders","volume":"34","author":"Jablensky","year":"2000","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011057.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-3565(25)24408-1","article-title":"Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties","volume":"244","author":"Janssen","year":"1988","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD011057.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"L103","DOI":"10.1016\/0024-3205(95)02037-J","article-title":"The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study","volume":"57","author":"Kapur","year":"1995","journal-title":"Life Sciences"},{"issue":"1-2","key":"10.1002\/14651858.CD011057.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02245603","article-title":"5-HT2 antagonism and EPS benefits: is there a causal connection?","volume":"124","author":"Kapur","year":"1996","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011057.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics?: a new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011057.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.comppsych.2009.03.008","article-title":"Cannabis abuse and severity of psychotic and affective disorders in Israeli psychiatric inpatients","volume":"51","author":"Katz","year":"2010","journal-title":"Comprehensive Psychiatry"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0110|cit110","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"2","key":"10.1002\/14651858.CD011057.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD011057.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.addbeh.2011.09.010","article-title":"Treatment of substance abusing patients with comorbid psychiatric disorders","volume":"37","author":"Kelly","year":"2012","journal-title":"Addictive Behaviors"},{"issue":"10","key":"10.1002\/14651858.CD011057.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.biopsych.2004.06.034","article-title":"The epidemiology of dual diagnosis","volume":"56","author":"Kessler","year":"2004","journal-title":"Biological Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011057.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/0165-6147(96)10024-9","article-title":"Neurochemical changes in cocaine withdrawal","volume":"17","author":"Kuhar","year":"1996","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0079-6123(08)00910-2","article-title":"Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis","volume":"172","author":"Kuroki","year":"2008","journal-title":"Progress in Brain Research"},{"issue":"10","key":"10.1002\/14651858.CD011057.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011057.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1600-0447.2005.00554.x","article-title":"The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis","volume":"112","author":"Lambert","year":"2005","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"32","key":"10.1002\/14651858.CD011057.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.2174\/138161212802884654","article-title":"Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder: a critical review","volume":"18","author":"Lazary","year":"2012","journal-title":"Current Pharmaceutical Design"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011057.pub2-BIB0119|cit119","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD011057.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD011057.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.2008.01308.x","article-title":"Definitions of response and remission in schizophrenia: recommendations for their use and their presentation","volume":"438","author":"Leucht","year":"2009","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"12","key":"10.1002\/14651858.CD011057.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0125|cit125","first-page":"594-602","article-title":"Manual for expanded Brief Psychiatric Rating Scale","volume":"12","author":"Lukoff","year":"1986","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0126|cit126","first-page":"40","article-title":"Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission","volume":"42","author":"Machielsen","year":"2009","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011057.pub2-BIB0128|cit128","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD011057.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/14656566.8.9.1211","article-title":"A preclinical and clinical rationale for quetiapine in mood syndromes","volume":"8","author":"McIntyre","year":"2007","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005053-198001000-00006","article-title":"An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index","volume":"168","author":"McLellan","year":"1980","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"0740-5472 (Prin","key":"10.1002\/14651858.CD011057.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The Fifth Edition of the Addiction Severity Index","volume":"9","author":"McLellan","year":"1992","journal-title":"J.Subst.Abuse Treat."},{"issue":"10","key":"10.1002\/14651858.CD011057.pub2-BIB0132|cit132","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004837.pub3","article-title":"Cannabis and schizophrenia","author":"McLoughlin","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD011057.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1192\/bjp.168.5.612","article-title":"Drug and alcohol problems among individuals with severe mental illness in south London","volume":"168","author":"Menezes","year":"1996","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011057.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/BF03033068","article-title":"Use of potentially abusive psychotropic substances in psychiatric inpatients","volume":"247","author":"Modestin","year":"1997","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"5","key":"10.1002\/14651858.CD011057.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/14656566.6.5.803","article-title":"Risperidone: a review","volume":"6","author":"Moller","year":"2005","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"11","key":"10.1002\/14651858.CD011057.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2165\/00003495-200767110-00003","article-title":"Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives","volume":"67","author":"Moller","year":"2007","journal-title":"Drugs"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011057.pub2-BIB0137|cit137","first-page":"133","article-title":"A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables","volume":"10","author":"Naber","year":"1995","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0138|cit138","first-page":"781","article-title":"Abnormal Involuntary Movement Scale (AIMS)","volume":"24","author":"National Institute of Mental Health Psychopharmacology Research Branch","year":"1988","journal-title":"Psychopharmacology Bulletin"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011057.pub2-BIB0139|cit139","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence","volume":"68","author":"Newcomer","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0140|cit140","volume-title":"Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update)","author":"National Collaborating Centre for Mental Health (UK)","year":"2009"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0141|cit141","volume-title":"Psychosis with Coexisting Substance Misuse: Assessment and Management in Adults and Young People","author":"National Collaborating Centre for Mental Health (UK)","year":"2011"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"8","key":"10.1002\/14651858.CD011057.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1176\/ps.47.8.853","article-title":"Medication noncompliance and substance abuse among patients with schizophrenia","volume":"47","author":"Owen","year":"1996","journal-title":"Psychiatric Services"},{"issue":"12","key":"10.1002\/14651858.CD011057.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.4088\/JCP.v63n1206","article-title":"Predictors of noncompliance in patients with schizophrenia","volume":"63","author":"Perkins","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011057.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.schres.2005.10.016","article-title":"Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode","volume":"83","author":"Perkins","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"1573-2509 (Elec","key":"10.1002\/14651858.CD011057.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.schres.2009.06.010","article-title":"Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis","volume":"113","author":"Potvin","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"19","key":"10.1002\/14651858.CD011057.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD011057.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archpsyc.1988.01800360017003","article-title":"The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures","volume":"45","author":"Robins","year":"1988","journal-title":"Archives of general psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD011057.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1176\/ajp.2006.163.12.2096","article-title":"Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes","volume":"163","author":"Robinson","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011057.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cpr.2009.06.002","article-title":"Clinical and laboratory assessment of the subjective experience of drug craving","volume":"29","author":"Rosenberg","year":"2009","journal-title":"Clinical Psychology Review"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1192\/bjp.177.2.149","article-title":"Definition and prevalence of severe and persistent mental illness","volume":"177","author":"Ruggeri","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011057.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0920-9964(00)00063-3","article-title":"Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia","volume":"48","author":"Salyers","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0153|cit153","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD011057.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0155|cit155","first-page":"InPress","article-title":"Study-based registers of randomized controlled trials: Starting a systematic review with data extraction or meta-analysis","volume":"InPress","author":"Shokraneh","year":"2017","journal-title":"BioImpacts"},{"issue":"0065-1591","key":"10.1002\/14651858.CD011057.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD011057.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/archpsyc.63.3.324","article-title":"Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes","volume":"63","author":"Sinha","year":"2006","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011057.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11920-011-0224-0","article-title":"New findings on biological factors predicting addiction relapse vulnerability","volume":"13","author":"Sinha","year":"2011","journal-title":"Current Psychiatry Reports"},{"issue":"1","key":"10.1002\/14651858.CD011057.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/schbul\/16.1.111","article-title":"Pharmacological treatment of substance-abusing schizophrenic patients","volume":"16","author":"Siris","year":"1990","journal-title":"Schizophrenia Bulletin"},{"issue":"9","key":"10.1002\/14651858.CD011057.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1177\/070674379704200920","article-title":"Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients","volume":"42","author":"Smelson","year":"1997","journal-title":"Canadian Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011057.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/070674370204700710","article-title":"Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence","volume":"47","author":"Smelson","year":"2002","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","article-title":"Timeline follow-back: a technique for assessing self-reported ethanol consumption","volume-title":"Measuring Alcohol Consuption: Psychosocial and Biological Methods","author":"Sobell","year":"1992"},{"issue":"6","key":"10.1002\/14651858.CD011057.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/BF02190250","article-title":"Prevalence of alcohol and drug abuse in schizophrenic inpatients","volume":"242","author":"Soyka","year":"1993","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"1","key":"10.1002\/14651858.CD011057.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health clinical antipsychotic trials of intervention effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD011057.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/10550490500528613","article-title":"Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders","volume":"15","author":"Stuyt","year":"2006","journal-title":"American Journal on Addictions"},{"issue":"10","key":"10.1002\/14651858.CD011057.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1185\/030079907X226050","article-title":"Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States","volume":"23","author":"Sun","year":"2007","journal-title":"Current Medical Research and Opinion"},{"issue":"4","key":"10.1002\/14651858.CD011057.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.2013.285063","article-title":"How to use a subgroup analysis: users' guide to the medical literature","volume":"311","author":"Sun","year":"2014","journal-title":"JAMA"},{"issue":"1-2","key":"10.1002\/14651858.CD011057.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0920-9964(95)00068-2","article-title":"Substance use: a powerful predictor of relapse in schizophrenia","volume":"20","author":"Swofford","year":"1996","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD011057.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.pnpbp.2005.11.027","article-title":"Theoretical insights into the mechanism of action of atypical antipsychotics","volume":"30","author":"Tort","year":"2006","journal-title":"Progress in Neuro-psychopharmacology & Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011057.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0091-3057(97)00445-0","article-title":"Mixed D2\/5-HT2A antagonism of cocaine-induced facilitation of brain stimulation reward","volume":"59","author":"Tsibulsky","year":"1998","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"2","key":"10.1002\/14651858.CD011057.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1524-4733.2006.00083.x","article-title":"Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial","volume":"9","author":"Tunis","year":"2006","journal-title":"Value Health"},{"issue":"5","key":"10.1002\/14651858.CD011057.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"1","key":"10.1002\/14651858.CD011057.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00127-004-0713-0","article-title":"Substance misuse at presentation to an early psychosis program","volume":"39","author":"Mastrigt","year":"2004","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"issue":"6627","key":"10.1002\/14651858.CD011057.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/386830a0","article-title":"Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects","volume":"386","author":"Volkow","year":"1997","journal-title":"Nature"},{"issue":"24","key":"10.1002\/14651858.CD011057.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"6583","DOI":"10.1523\/JNEUROSCI.1544-06.2006","article-title":"Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction","volume":"26","author":"Volkow","year":"2006","journal-title":"Journal of Neuroscience"},{"issue":"46","key":"10.1002\/14651858.CD011057.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"12700","DOI":"10.1523\/JNEUROSCI.3371-07.2007","article-title":"Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement","volume":"27","author":"Volkow","year":"2007","journal-title":"Journal of Neuroscience"},{"issue":"37","key":"10.1002\/14651858.CD011057.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"15037","DOI":"10.1073\/pnas.1010654108","article-title":"Addiction: beyond dopamine reward circuitry","volume":"108","author":"Volkow","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1002\/14651858.CD011057.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/00048674.2010.545984","article-title":"Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: a review","volume":"45","author":"Vothknecht","year":"2011","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.bp.105.017236","article-title":"Substance misuse in first-episode psychosis: 15-month prospective follow-up study","volume":"189","author":"Wade","year":"2006","journal-title":"British Journal of Psychiatry"},{"issue":"21","key":"10.1002\/14651858.CD011057.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMsr077003","article-title":"Statistics in medicine - reporting of subgroup analyses in clinical trials","volume":"357","author":"Wang","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011057.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archpsyc.1990.01810210069010","article-title":"Changes in mood, craving, and sleep during short-term abstinence reported by male cocaine addicts. A controlled, residential study","volume":"47","author":"Weddington","year":"1990","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011057.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4314\/ajpsy.v12i3.48496","article-title":"Occurrence of comorbid substance use disorders among acute psychiatric inpatients at Stikland Hospital in the Western Cape, South Africa","volume":"12","author":"Weich","year":"2009","journal-title":"African Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011057.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1517\/14656560802694655","article-title":"Pharmacotherapy of patients with schizophrenia and substance abuse","volume":"10","author":"Wobrock","year":"2009","journal-title":"Expert Opinion in Pharmacology"},{"issue":"7","key":"10.1002\/14651858.CD011057.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD011057.pub2-BIB0185|cit185","first-page":"40","article-title":"Atypical antipsychotics in bipolar depression: potential mechanisms of action","volume":"66","author":"Yatham","year":"2005","journal-title":"Journal of Clinical Psychiatry"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011057.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T23:34:44Z","timestamp":1751240084000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011057.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,22]]},"references-count":185,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011057.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,22]]}}}